Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome (NCT06256289) | Clinical Trial Compass
UnknownPhase 4
Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome
50 participantsStarted 2024-03-31
Plain-language summary
The goal of this clinical trial is to investigate the use of ultra-high performance liquid chromatography-mass spectrometry for metabolomics and proteomics research in patients with Polycystic Ovary Syndrome (PCOS) and Non-Alcoholic Fatty Liver Disease (NAFLD). The main questions it aims to answer are:
* How can this technology help identify specific biomarkers for diagnosing PCOS combined with NAFLD?
* What is the role of Canagliflozin in improving the safety and efficacy of treatment for PCOS and NAFLD patients?
Participants, who are 50 non-diabetic women with PCOS, will undergo a series of assessments including cardiovascular metabolic indicators, liver NAFLD screening risk stratification, and insulin resistance index. They will be compared with 50 age and BMI-matched healthy controls. The participants will be randomized to receive either CANA/MET (Canagliflozin 100 mg daily plus Metformin 1000 mg twice daily) or MET (Metformin 1000 mg twice daily) for a continuous period of three months. The study will evaluate various parameters including menstrual patterns, anthropometric parameters, gonadal parameters, glucose-lipid homeostasis, liver enzyme indices, non-invasive hepatic fat changes, metabolomics, and NAFLD-related indicators.
Who can participate
Age range18 Years – 45 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. aged 18-45 years old;
✓. Body mass index (BMI) more than 18.5 kg / m2;
✓. PCOS diagnosis meets Rotterdam 2003 criteria: at least two of the following symptoms: menstrual menstruation / amenorrhea, hyperandrogenism, and / or biochemical and / or clinical signs of polycystic ovaries.
✓. The serum pregnancy test was negative before enrollment.
✓. Clinical diagnosis of fatty liver: the ratio of liver to kidney is greater than 1.0.
Exclusion criteria
✕. Less than 18 years old or more than 45 years old;
✕. Patients who are pregnant, intend to become pregnant, are breastfeeding or giving birth;
✕. Drug history in the past three months included oral contraceptives, sodium-dependent glucose transporters 2 inhibitors, glucagon-like peptide-1 receptor agonists, thiazolidinediones, metformin, corticosteroids or traditional Chinese medicine.
✕
What they're measuring
1
liver steatosis index CAP (Controlled Attenuation Parameter) measured by FibroScan
. Endocrine disorders such as hyperprolactinemia, thyroid dysfunction and diabetes, Cushing's syndrome, 21-hydroxylase deficiency, congenital adrenal hyperplasia, androgen-secreting tumors, cervical, endometrial or breast cancer.
✕. Severe liver function (alanine aminase, aspartate aminase\> 3 times normal value or elevation of serum bilirubin to more than 3 times the upper limit of normal) or renal impairment (eGFR \<60 ml/min/1.73m2).Severe cardiopulmonary, hematopoietic and hematopoietic insufficiency.
✕. Current or past (most recent three months) participation in other studies.
✕. Viral hepatitis, autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, hemochromatosis, anti-trypsin defense, Wilson disease, parenteral nutrition history, use of drugs known to cause steatosis (such as valproate, amiodarone or vitamin E) or liver injury caused by drug abuse.Clinical evidence of hepatic decompensation, such as hepatic encephalopathy, ascites, and variceal bleeding.